Sharon L. Giles1,
Christina Messiou1, David John Collins1, 2,
Veronica A. Morgan1, Faith E. Davies3, 4,
Gareth Morgan3, 4, Nandita M. deSouza, 12
1MRI
Department, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; 2Clinical
Magnetic Resonance, Institute of Cancer Research, Sutton, Surrey, United
Kingdom; 3Haemato-oncology Department, Royal Marsden Hospital,
Sutton, Surrey, United Kingdom; 4Molecular Pathology, Institute of
Cancer Research, Sutton, Surrey, United Kingdom
WB-DWI offers an alternative to serum paraproteins and bone trephine for response assessment in myeloma. This prospective study compared image appearances, mean ADCs and histogram characteristics of volumetric marrow segmentions in myeloma patients pre and post treatment, using laboratory tests as the gold standard to define response. There were significant differences in ADC change between responders and non-responders (14% increase vs 6% decrease, p=0.008), with a strong correlation between change in ADC and laboratory markers of response (r = -0.77, p<0.001). WB-DWI is a useful biomarker of response, but relative roles for qualitative and quantitative analysis need to be determined.